{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:55:55Z","timestamp":1789498555631,"version":"build-2803163510"},"reference-count":127,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Medullary thyroid carcinoma is a rare neuroendocrine tumor originating from calcitonin-secreting parafollicular C cells of the thyroid gland. Approximately 25% of cases in adults are hereditary medullary thyroid carcinoma (hMTC), arising from activating, germline pathogenic variants in the REarranged during Transfection (RET) proto-oncogene and causing the syndromes multiple endocrine neoplasia (MEN) types 2A and 2B. A paradigmatic feature of MEN2 is its robust genotype-phenotype correlations, which predict the disease spectrum and age of onset of hMTC and other clinical manifestations. Advances in genetic testing and systemic therapies and an improved understanding of the natural course of MEN2 have transformed the clinical presentation of hMTC from advanced-stage disease to early detection in asymptomatic RET pathogenic variant carriers. The management of hMTC has similarly evolved from aggressive, one-size-fits-all surgical approaches to personalized strategies informed by genotype, biochemical markers, and imaging findings. Risk-reducing early thyroidectomy remains the cornerstone of metastatic hMTC prevention, with the timing of surgery tailored to the specific pathogenic variant and clinical context. Additionally, recent advances in targeted systemic therapies offer promising options for patients with recurrent and\/or metastatic disease. This \u201cApproach to the Patient\u201d article explores the diagnostic evaluation, surgical decision-making, systemic treatment options, and follow-up of patients with hMTC, emphasizing the critical role of multidisciplinary care in optimizing outcomes for patients and their families.<\/jats:p>","DOI":"10.1210\/clinem\/dgaf089","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T13:53:26Z","timestamp":1742392406000},"page":"2685-2697","source":"Crossref","is-referenced-by-count":6,"title":["Approach to the Patient: Hereditary Medullary Thyroid Carcinoma"],"prefix":"10.1210","volume":"110","author":[{"given":"Omair A","family":"Shariq","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Section of Surgical Endocrinology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G","family":"Waguespack","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]},{"name":"Department of Pediatrics-Patient Care, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hamidi","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin C","family":"Kensing","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Section of Surgical Endocrinology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi I","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M","family":"Skefos","sequence":"additional","affiliation":[{"name":"Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5933-1005","authenticated-orcid":false,"given":"Nancy D","family":"Perrier","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Section of Surgical Endocrinology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"2025081215531957200_dgaf089-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-22542-5_1","article-title":"Thyroid C-cell biology and oncogenic transformation","volume":"204","author":"Cote","year":"2015","journal-title":"Recent Results Cancer Res"},{"issue":"1","key":"2025081215531957200_dgaf089-B2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/jcem-19-1-152","article-title":"Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity","volume":"19","author":"Hazard","year":"1959","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025081215531957200_dgaf089-B3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJM197308302890901","article-title":"C-cell hyperplasia preceding medullary thyroid carcinoma","volume":"289","author":"Wolfe","year":"1973","journal-title":"N Engl J Med"},{"issue":"10","key":"2025081215531957200_dgaf089-B4","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrendo.2011.139","article-title":"Management of medullary thyroid carcinoma and MEN2 syndromes in childhood","volume":"7","author":"Waguespack","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"16","key":"2025081215531957200_dgaf089-B5","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa012915","article-title":"Early malignant progression of hereditary medullary thyroid cancer","volume":"349","author":"Machens","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"2025081215531957200_dgaf089-B6","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4183\/aeb.2019.544","article-title":"CALCITONIN REVISITED IN 2020","volume":"15","author":"Danila","year":"2019","journal-title":"Acta Endocrinol (Buchar)"},{"issue":"5","key":"2025081215531957200_dgaf089-B7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z","article-title":"Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems","volume":"88","author":"Kebebew","year":"2000","journal-title":"Cancer"},{"issue":"6","key":"2025081215531957200_dgaf089-B8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1530\/EC-18-0157","article-title":"Incidence and prevalence of sporadic and hereditary MTC in Denmark 1960\u20132014: a nationwide study","volume":"7","author":"Mathiesen","year":"2018","journal-title":"Endocr Connect"},{"issue":"6","key":"2025081215531957200_dgaf089-B9","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/1097-0142(19890315)63:6<1196::AID-CNCR2820630626>3.0.CO;2-O","article-title":"Clinical characteristics in sporadic and familial medullary thyroid carcinoma. A nationwide study of 249 patients in Sweden from 1959 through 1981","volume":"63","author":"Bergholm","year":"1989","journal-title":"Cancer"},{"issue":"9","key":"2025081215531957200_dgaf089-B10","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1210\/clinem\/dgae133","article-title":"Pediatric medullary thyroid carcinoma: clinical presentations and long-term outcomes in 144 patients over 6 decades","volume":"109","author":"Hensley","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025081215531957200_dgaf089-B11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1210\/jcem.82.1.3707","article-title":"C cell hyperplasia\/neoplasia","volume":"82","author":"LiVolsi","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025081215531957200_dgaf089-B12","doi-asserted-by":"crossref","first-page":"e3582","DOI":"10.1210\/clinem\/dgab326","article-title":"Similar stage-dependent survival and outcome in sporadic and hereditary medullary thyroid carcinoma","volume":"106","author":"Raue","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025081215531957200_dgaf089-B13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/EJE-18-1008","article-title":"Clinico-pathologic and dynamic prognostic factors in sporadic and familial medullary thyroid carcinoma: an Israeli multi-center study","volume":"181","author":"Twito","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2025081215531957200_dgaf089-B14","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1073\/pnas.91.4.1579","article-title":"Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B","volume":"91","author":"Carlson","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6461","key":"2025081215531957200_dgaf089-B15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/367375a0","article-title":"A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma","volume":"367","author":"Hofstra","year":"1994","journal-title":"Nature"},{"issue":"6428","key":"2025081215531957200_dgaf089-B16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"issue":"7","key":"2025081215531957200_dgaf089-B17","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC","volume":"2","author":"Donis-Keller","year":"1993","journal-title":"Hum Mol Genet"},{"issue":"8","key":"2025081215531957200_dgaf089-B18","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/07853890701646256","article-title":"Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases","volume":"39","author":"Runeberg-Roos","year":"2007","journal-title":"Ann Med"},{"issue":"6","key":"2025081215531957200_dgaf089-B19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American thyroid association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"issue":"11","key":"2025081215531957200_dgaf089-B20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/jmg.37.11.817","article-title":"Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis","volume":"37","author":"Hansford","year":"2000","journal-title":"J Med Genet"},{"issue":"5","key":"2025081215531957200_dgaf089-B21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2006-0017","article-title":"RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors","volume":"27","author":"de Groot","year":"2006","journal-title":"Endocr Rev"},{"issue":"8","key":"2025081215531957200_dgaf089-B22","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.cellsig.2014.03.032","article-title":"Mechanisms of RET signaling in cancer: current and future implications for targeted therapy","volume":"26","author":"Plaza-Menacho","year":"2014","journal-title":"Cell Signal"},{"issue":"1","key":"2025081215531957200_dgaf089-B23","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1152\/ajpgi.00452.2012","article-title":"Enteric nervous system development: migration, differentiation, and disease","volume":"305","author":"Lake","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"2025081215531957200_dgaf089-B24","doi-asserted-by":"crossref","first-page":"T29","DOI":"10.1530\/ERC-17-0209","article-title":"A comprehensive review on MEN2B","volume":"25","author":"Castinetti","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"2025081215531957200_dgaf089-B25","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1210\/jc.2013-1204","article-title":"Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update","volume":"98","author":"Wells","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025081215531957200_dgaf089-B26","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3390\/cancers15072125","article-title":"Primary hyperparathyroidism in multiple endocrine neoplasia type 2A in Denmark 1930\u20132021: a nationwide population-based retrospective study","volume":"15","author":"Holm","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"19","key":"2025081215531957200_dgaf089-B27","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jama.1996.03540190047028","article-title":"The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis","volume":"276","author":"Eng","year":"1996","journal-title":"JAMA"},{"issue":"2","key":"2025081215531957200_dgaf089-B28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1046\/j.1365-2265.2003.01782.x","article-title":"Frequent association between MEN 2A and cutaneous lichen amyloidosis","volume":"59","author":"Verga","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2025081215531957200_dgaf089-B29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jpedsurg.2007.09.043","article-title":"RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds","volume":"43","author":"Fialkowski","year":"2008","journal-title":"J Pediatr Surg"},{"issue":"12","key":"2025081215531957200_dgaf089-B30","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"Guidelines for diagnosis and therapy of MEN type 1 and type 2","volume":"86","author":"Brandi","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025081215531957200_dgaf089-B31","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1210\/jc.2019-00516","article-title":"Long-term outcomes and aggressiveness of hereditary medullary thyroid carcinoma: 40 years of experience at one center","volume":"104","author":"Raue","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025081215531957200_dgaf089-B32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-8587(18)30336-X","article-title":"Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study","volume":"7","author":"Castinetti","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2025081215531957200_dgaf089-B33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1245\/s10434-007-9665-4","article-title":"Failure to recognize multiple endocrine neoplasia 2B: more common than we think?","volume":"15","author":"Wray","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"2025081215531957200_dgaf089-B34","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.surg.2008.08.028","article-title":"Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis","volume":"144","author":"Brauckhoff","year":"2008","journal-title":"Surgery"},{"issue":"12","key":"2025081215531957200_dgaf089-B35","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00268-004-7637-4","article-title":"Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease","volume":"28","author":"Brauckhoff","year":"2004","journal-title":"World J Surg"},{"issue":"1","key":"2025081215531957200_dgaf089-B36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cncr.10205","article-title":"Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course","volume":"94","author":"Leboulleux","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"2025081215531957200_dgaf089-B37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1210\/jc.2017-01884","article-title":"Long-term survivorship in multiple endocrine neoplasia type 2B diagnosed before and in the new millennium","volume":"103","author":"Raue","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025081215531957200_dgaf089-B38","first-page":"3740","article-title":"Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma","volume":"81","author":"Wohllk","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025081215531957200_dgaf089-B39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2265.2010.03900.x","article-title":"RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)","volume":"74","author":"Romei","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025081215531957200_dgaf089-B40","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ghir.2004.03.033","article-title":"Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2)","volume":"14","author":"Jimenez","year":"2004","journal-title":"Growth Horm IGF Res"},{"issue":"6","key":"2025081215531957200_dgaf089-B41","first-page":"1076","article-title":"Parent-of-origin effects in multiple endocrine neoplasia type 2B","volume":"55","author":"Carlson","year":"1994","journal-title":"Am J Hum Genet"},{"issue":"20","key":"2025081215531957200_dgaf089-B42","doi-asserted-by":"crossref","first-page":"10179","DOI":"10.1158\/0008-5472.CAN-06-0884","article-title":"RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B","volume":"66","author":"Cranston","year":"2006","journal-title":"Cancer Res"},{"issue":"2","key":"2025081215531957200_dgaf089-B43","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2000-5806","article-title":"A RET double mutation in the germline of a kindred with FMTC","volume":"108","author":"Bartsch","year":"2000","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"8","key":"2025081215531957200_dgaf089-B44","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1055\/s-2000-11001","article-title":"A patient with MEN 2 and multiple mutations of RET in the germline","volume":"108","author":"Koch","year":"2000","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"9","key":"2025081215531957200_dgaf089-B45","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/hmg\/ddw057","article-title":"Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression","volume":"25","author":"Smith","year":"2016","journal-title":"Hum Mol Genet"},{"key":"2025081215531957200_dgaf089-B46","article-title":"ClinVar: RET gene","author":"National Center for Biotechnology Information (NCBI)","year":"2024"},{"issue":"2","key":"2025081215531957200_dgaf089-B47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1530\/EJE-10-0333","article-title":"Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes","volume":"163","author":"Romei","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025081215531957200_dgaf089-B48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/hmg\/7.1.129","article-title":"Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation","volume":"7","author":"Decker","year":"1998","journal-title":"Hum Mol Genet"},{"issue":"11","key":"2025081215531957200_dgaf089-B49","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1210\/jc.2017-02529","article-title":"P.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer","volume":"103","author":"Loveday","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"7809","key":"2025081215531957200_dgaf089-B50","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"issue":"2","key":"2025081215531957200_dgaf089-B51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1089\/thy.2010.0328","article-title":"Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation","volume":"21","author":"Jasim","year":"2011","journal-title":"Thyroid"},{"issue":"6","key":"2025081215531957200_dgaf089-B52","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1210\/jc.2016-3640","article-title":"Risk profile of the RET A883F germline mutation: an international collaborative study","volume":"102","author":"Mathiesen","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025081215531957200_dgaf089-B53","doi-asserted-by":"crossref","first-page":"e734","DOI":"10.1210\/clinem\/dgad156","article-title":"The changing face of multiple endocrine neoplasia 2A: from symptom-based to preventative medicine","volume":"108","author":"Machens","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025081215531957200_dgaf089-B54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CCO.0000000000001009","article-title":"Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results","volume":"36","author":"Machens","year":"2024","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"2025081215531957200_dgaf089-B55","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1210\/jc.2018-02102","article-title":"Fifty years after the first description, MEN 2B syndrome diagnosis is still late: descriptions of two recent cases","volume":"104","author":"Elisei","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025081215531957200_dgaf089-B56","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1089\/thy.2022.0189","article-title":"Preoperative identification of medullary thyroid carcinoma (MTC): clinical validation of the afirma MTC RNA-sequencing classifier","volume":"32","author":"Randolph","year":"2022","journal-title":"Thyroid"},{"issue":"8","key":"2025081215531957200_dgaf089-B57","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/cncr.31245","article-title":"Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules","volume":"124","author":"Nikiforova","year":"2018","journal-title":"Cancer"},{"key":"2025081215531957200_dgaf089-B58","doi-asserted-by":"crossref","first-page":"1418657","DOI":"10.3389\/fendo.2024.1418657","article-title":"Management of medullary thyroid cancer based on variation of carcinoembryonic antigen and calcitonin","volume":"15","author":"Wang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2025081215531957200_dgaf089-B59","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1590\/S1807-59322009000700015","article-title":"Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma","volume":"64","author":"Toledo","year":"2009","journal-title":"Clinics (Sao Paulo)"},{"issue":"2","key":"2025081215531957200_dgaf089-B60","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/jc.2006-1590","article-title":"Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules","volume":"92","author":"Costante","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025081215531957200_dgaf089-B61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hed.21405","article-title":"Spurious hypercalcitoninemia and heterophilic antibodies in patients with thyroid nodules","volume":"33","author":"Giovanella","year":"2011","journal-title":"Head Neck"},{"issue":"2","key":"2025081215531957200_dgaf089-B62","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1210\/jc.2005-1429","article-title":"\u201cHook effect\u201d in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature","volume":"91","author":"Leboeuf","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025081215531957200_dgaf089-B63","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1089\/thy.2007.0231","article-title":"Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature","volume":"18","author":"Dora","year":"2008","journal-title":"Thyroid"},{"issue":"6","key":"2025081215531957200_dgaf089-B64","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MNM.0b013e3283384587","article-title":"Role of [18F]FDG-PET\/CT in the detection of occult recurrent medullary thyroid cancer","volume":"31","author":"Skoura","year":"2010","journal-title":"Nucl Med Commun"},{"issue":"4","key":"2025081215531957200_dgaf089-B65","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2967\/jnumed.106.036681","article-title":"Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels","volume":"48","author":"Ong","year":"2007","journal-title":"J Nucl Med"},{"issue":"4","key":"2025081215531957200_dgaf089-B66","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.semnuclmed.2023.01.003","article-title":"Update on management of medullary thyroid carcinoma: focus on nuclear medicine","volume":"53","author":"Treglia","year":"2023","journal-title":"Semin Nucl Med"},{"issue":"1","key":"2025081215531957200_dgaf089-B67","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12020-022-03062-3","article-title":"Prospective study on the clinical relevance of 18F-DOPA positron emission tomography\/computed tomography in patients with medullary thyroid carcinoma","volume":"77","author":"Califano","year":"2022","journal-title":"Endocrine"},{"issue":"6","key":"2025081215531957200_dgaf089-B68","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/humu.23430","article-title":"Genotype-specific progression of hereditary medullary thyroid cancer","volume":"39","author":"Machens","year":"2018","journal-title":"Hum Mutat"},{"issue":"6","key":"2025081215531957200_dgaf089-B69","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MPA.0b013e3181ebb4f0","article-title":"The North American neuroendocrine tumor society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer","volume":"39","author":"Chen","year":"2010","journal-title":"Pancreas"},{"issue":"5","key":"2025081215531957200_dgaf089-B70","doi-asserted-by":"crossref","first-page":"512","DOI":"10.6004\/jnccn.2010.0040","article-title":"Medullary carcinoma","volume":"8","author":"Tuttle","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2025081215531957200_dgaf089-B71","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: management guidelines of the American thyroid association","volume":"19","author":"Kloos","year":"2009","journal-title":"Thyroid"},{"issue":"2","key":"2025081215531957200_dgaf089-B72","doi-asserted-by":"crossref","first-page":"T41","DOI":"10.1530\/ERC-17-0202","article-title":"Advances in risk-oriented surgery for multiple endocrine neoplasia type 2","volume":"25","author":"Machens","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2025081215531957200_dgaf089-B73","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa043999","article-title":"Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A","volume":"353","author":"Skinner","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"2025081215531957200_dgaf089-B74","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/ERC-20-0108","article-title":"HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: early thyroidectomy in multiple endocrine neoplasia: a four decade experience","volume":"27","author":"Grubbs","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2025081215531957200_dgaf089-B75","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1002\/bjs.10746","article-title":"Long-term outcome of prophylactic thyroidectomy in children carrying RET germline mutations","volume":"105","author":"Machens","year":"2018","journal-title":"Br J Surg"},{"issue":"6","key":"2025081215531957200_dgaf089-B76","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.surg.2012.08.056","article-title":"Long-term follow-up data may help manage patient and parent expectations for pediatric patients undergoing thyroidectomy","volume":"152","author":"Morris","year":"2012","journal-title":"Surgery"},{"issue":"13","key":"2025081215531957200_dgaf089-B77","doi-asserted-by":"crossref","first-page":"8863","DOI":"10.1245\/s10434-021-10383-6","article-title":"Surgeon volume and long-term oncologic outcomes in patients with medullary thyroid carcinoma","volume":"28","author":"Park","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"2025081215531957200_dgaf089-B78","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1002\/cncr.24941","article-title":"Multiple endocrine neoplasia [corrected] syndrome type 2B in early childhood: long-term benefit of prophylactic thyroidectomy","volume":"116","author":"Waguespack","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"2025081215531957200_dgaf089-B79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1245\/s10434-012-2589-7","article-title":"Ultrasonography should not guide the timing of thyroidectomy in pediatric patients diagnosed with multiple endocrine neoplasia syndrome 2A through genetic screening","volume":"20","author":"Morris","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2025081215531957200_dgaf089-B80","doi-asserted-by":"crossref","first-page":"T69","DOI":"10.1530\/ERC-17-0335","article-title":"Patient quality of life and prognosis in multiple endocrine neoplasia type 2","volume":"25","author":"Grey","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"2025081215531957200_dgaf089-B81","doi-asserted-by":"crossref","first-page":"L63","DOI":"10.1530\/ERC-17-0189","article-title":"The penetrance of MEN2 pheochromocytoma is not only determined by RET mutations","volume":"24","author":"Castinetti","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"2025081215531957200_dgaf089-B82","doi-asserted-by":"crossref","first-page":"e240038","DOI":"10.1530\/ERC-24-0038","article-title":"Genotype-specific development of MEN 2 constituent components in 683 RET carriers","volume":"31","author":"Machens","year":"2024","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2025081215531957200_dgaf089-B83","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1210\/jc.2004-1836","article-title":"Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level","volume":"90","author":"Machens","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025081215531957200_dgaf089-B84","doi-asserted-by":"crossref","first-page":"bvae084","DOI":"10.1210\/jendso\/bvae084","article-title":"Medullary thyroid cancer: epidemiology and characteristics according to data from the Marne-Ardennes register 1975\u20132018","volume":"8","author":"Caill\u00e9","year":"2024","journal-title":"J Endocr Soc"},{"issue":"2","key":"2025081215531957200_dgaf089-B85","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/SLA.0b013e3181ae333f","article-title":"Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels","volume":"250","author":"Machens","year":"2009","journal-title":"Ann Surg"},{"issue":"2","key":"2025081215531957200_dgaf089-B86","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1210\/jc.2011-2046","article-title":"The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center","volume":"97","author":"Elisei","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025081215531957200_dgaf089-B87","doi-asserted-by":"crossref","first-page":"E509","DOI":"10.1210\/jc.2010-1234","article-title":"Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the groupe francais d'Etude des tumeurs endocrines","volume":"96","author":"Rohmer","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"2025081215531957200_dgaf089-B88","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.3390\/cancers16193343","article-title":"The value of pretherapeutic basal calcitonin cut-offs for the therapeutic strategy and prediction of long-term outcome of patients with medullary thyroid cancer\u2014a 30-year single-center experience","volume":"16","author":"Niederle","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2025081215531957200_dgaf089-B89","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/EC-20-0163","article-title":"Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study","volume":"9","author":"Larsen","year":"2020","journal-title":"Endocr Connect"},{"issue":"11","key":"2025081215531957200_dgaf089-B90","doi-asserted-by":"crossref","first-page":"E1813","DOI":"10.1210\/jc.2013-1653","article-title":"The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2","volume":"98","author":"Thosani","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025081215531957200_dgaf089-B91","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hed.24969","article-title":"Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer","volume":"40","author":"Pena","year":"2018","journal-title":"Head Neck"},{"issue":"6","key":"2025081215531957200_dgaf089-B92","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0039-6060(96)80042-0","article-title":"Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A","volume":"120","author":"Herfarth","year":"1996","journal-title":"Surgery"},{"issue":"11","key":"2025081215531957200_dgaf089-B93","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jbmr.4677","article-title":"Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2025081215531957200_dgaf089-B94","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nrendo.2012.38","article-title":"Advances in the follow-up of differentiated or medullary thyroid cancer","volume":"8","author":"Elisei","year":"2012","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"2025081215531957200_dgaf089-B95","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1210\/jc.2005-0044","article-title":"Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma","volume":"90","author":"Barbet","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025081215531957200_dgaf089-B96","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1089\/thy.2014.0028","article-title":"Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement","volume":"24","author":"Jonklaas","year":"2014","journal-title":"Thyroid"},{"issue":"4","key":"2025081215531957200_dgaf089-B97","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00000658-199010000-00002","article-title":"Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma","volume":"212","author":"van Heerden","year":"1990","journal-title":"Ann Surg"},{"issue":"5","key":"2025081215531957200_dgaf089-B98","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s00268-007-9317-7","article-title":"Long-term outcome of reoperations for medullary thyroid carcinoma","volume":"32","author":"Fialkowski","year":"2008","journal-title":"World J Surg"},{"issue":"5","key":"2025081215531957200_dgaf089-B99","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-12-0943","article-title":"Radioactive iodine in the treatment of medullary thyroid carcinoma: a controlled multicenter study","volume":"168","author":"Meijer","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2025081215531957200_dgaf089-B100","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/er.2019-00007","article-title":"Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond","volume":"40","author":"Cabanillas","year":"2019","journal-title":"Endocr Rev"},{"issue":"8","key":"2025081215531957200_dgaf089-B101","doi-asserted-by":"crossref","first-page":"luae103","DOI":"10.1210\/jcemcr\/luae103","article-title":"Paraneoplastic diarrhea from medullary thyroid carcinoma resolved with yttrium-90 radioembolization of liver metastases","volume":"2","author":"Hamidi","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"6","key":"2025081215531957200_dgaf089-B102","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1210\/jc.2009-2461","article-title":"Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"95","author":"Robinson","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025081215531957200_dgaf089-B103","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025081215531957200_dgaf089-B104","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025081215531957200_dgaf089-B105","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1158\/1078-0432.CCR-17-2101","article-title":"Outcomes of children and adolescents with advanced hereditary medullary thyroid carcinoma treated with vandetanib","volume":"24","author":"Kraft","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2025081215531957200_dgaf089-B106","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1158\/1078-0432.CCR-13-0071","article-title":"Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma","volume":"19","author":"Fox","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"29","key":"2025081215531957200_dgaf089-B107","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025081215531957200_dgaf089-B108","doi-asserted-by":"crossref","first-page":"e27077","DOI":"10.1002\/pbc.27077","article-title":"A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: trial ADVL1211, a report from the children\u2019s oncology group","volume":"65","author":"Chuk","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2025081215531957200_dgaf089-B109","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2025081215531957200_dgaf089-B110","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1089\/thy.2013.0137","article-title":"In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer","volume":"23","author":"Bentzien","year":"2013","journal-title":"Thyroid"},{"issue":"36","key":"2025081215531957200_dgaf089-B111","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors","volume":"23","author":"Carlomagno","year":"2004","journal-title":"Oncogene"},{"issue":"27","key":"2025081215531957200_dgaf089-B112","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.23.02503","article-title":"Durability of response with selpercatinib in patients with RET-activated thyroid cancer: long-term safety and efficacy from LIBRETTO-001","volume":"42","author":"Wirth","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025081215531957200_dgaf089-B113","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2025081215531957200_dgaf089-B114","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/thy.2023.0363","article-title":"Pralsetinib in patients with advanced\/metastatic rearranged during transfection (RET)-altered thyroid cancer: updated efficacy and safety data from the ARROW study","volume":"34","author":"Subbiah","year":"2024","journal-title":"Thyroid"},{"issue":"8","key":"2025081215531957200_dgaf089-B115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2025081215531957200_dgaf089-B116","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ando.2024.02.001","article-title":"RET kinase inhibitors for the treatment of RET-altered thyroid cancers: current knowledge and future directions","volume":"85","author":"Hamidi","year":"2024","journal-title":"Ann Endocrinol (Paris)"},{"issue":"7","key":"2025081215531957200_dgaf089-B117","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-driven cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov"},{"issue":"8","key":"2025081215531957200_dgaf089-B118","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"2025081215531957200_dgaf089-B119","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/thy.2024.0495","article-title":"Efficacy and safety of selective RET inhibitors in patients with advanced hereditary medullary thyroid carcinoma","volume":"35","author":"Hamidi","year":"2025","journal-title":"Thyroid"},{"key":"2025081215531957200_dgaf089-B120","author":"National Comprehensive Cancer Network"},{"issue":"4","key":"2025081215531957200_dgaf089-B121","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1245\/s10434-023-14854-w","article-title":"Selpercatinib before surgery for the treatment of RET-altered thyroid cancers","volume":"31","author":"Sarvestani","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"2025081215531957200_dgaf089-B122","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"2025081215531957200_dgaf089-B123","doi-asserted-by":"crossref","first-page":"102372","DOI":"10.1016\/j.ctrv.2022.102372","article-title":"Resistance to RET targeted therapy in thyroid cancer: molecular basis and overcoming strategies","volume":"105","author":"Rom\u00e1n-Gil","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"2025081215531957200_dgaf089-B124","doi-asserted-by":"crossref","first-page":"e2300053","DOI":"10.1200\/PO.23.00053","article-title":"Patterns of treatment failure after selective rearranged during transfection (RET) inhibitors in patients with metastatic medullary thyroid carcinoma","volume":"7","author":"Hadoux","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"2025081215531957200_dgaf089-B125","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2017-00317","article-title":"Medullary thyroid carcinoma in MEN2A: ATA moderate- or high-risk RET mutations do not predict disease aggressiveness","volume":"102","author":"Voss","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025081215531957200_dgaf089-B126","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.ejso.2020.09.004","article-title":"Lymph node metastasis in hereditary medullary thyroid cancer is independent of the underlying RET germline mutation","volume":"47","author":"Machens","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"2025081215531957200_dgaf089-B127","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12020-021-02895-8","article-title":"Controversy on the management of patients carrying RET p.V804M mutation","volume":"75","author":"Alzahrani","year":"2022","journal-title":"Endocrine"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf089\/62462884\/dgaf089.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/9\/2685\/62462884\/dgaf089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/9\/2685\/62462884\/dgaf089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T19:53:40Z","timestamp":1755028420000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/9\/2685\/8086923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":127,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,3,19]]},"published-print":{"date-parts":[[2025,8,7]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf089","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,3,19]]}}}